A Multi-center, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Tolerability of KRP203 in Patients With Active Subacute Cutaneous Lupus Erythematosus.

Trial Profile

A Multi-center, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Tolerability of KRP203 in Patients With Active Subacute Cutaneous Lupus Erythematosus.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs KRP 203 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 15 Apr 2016 Status changed from discontinued to completed.
    • 01 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 26 Sep 2012 Planned End Date changed from 1 Jul 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top